Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate

Jenny H. Humphreys, Alexander Warner, Ruth Costello, Mark Lunt, Suzanne Verstappen, William Dixon

Research output: Contribution to journalArticlepeer-review


Background Patients with rheumatoid arthritis (RA) who take methotrexate (MTX) are advised to limit their alcohol intake due to potential combined hepatotoxicity. However, data are limited to support this. The aim of this study was to quantify the risk of developing abnormal liver blood tests at different levels of alcohol consumption, using routinely collected data from primary care. Methods Patients with RA in the Clinical Practice Research Datalink starting MTX between 1987 and 2016 were included. Hepatotoxicity was defined as transaminitis: alanine transaminase or aspartate aminotransferase more than three times the upper limit of normal. Crude rates of transaminitis were calculated per 1000 person-years, categorised by weekly alcohol consumption in units. Cox proportional hazard models tested the association between alcohol consumption and transaminitis univariately, then age and gender adjusted. Results 11 839 patients were included, with 530 episodes of transaminitis occurring in 47 090 person-years follow-up. Increased weekly alcohol consumption as a continuous variable was associated with increased risk of transaminitis, adjusted HR (95% CI) per unit consumed 1.01 (1.00 to 1.02); consuming between 15 and 21 units was associated with a possible increased risk of hepatotoxicity, while drinking >21 units per week significantly increased rates of transaminitis, adjusted HR (95% CI) 1.85 (1.17 to 2.93). Conclusions Weekly alcohol consumption of <14 units per week does not appear to be associated with an increased risk of transaminitis.
Original languageEnglish
JournalAnnals of the rheumatic diseases
Early online date23 Mar 2017
Publication statusPublished - 2017


Dive into the research topics of 'Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate'. Together they form a unique fingerprint.

Cite this